Literature DB >> 12014625

Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.

Peter Hau1, Rainer Apfel, Petra Wiese, Ines Tschertner, Armin Blesch, Ulrich Bogdahn.   

Abstract

BACKGROUND: The identification of tumor-specific antigens is an important topic for potential therapeutic and diagnostic applications. Melanoma-inhibiting activity (MIA/CD-RAP), a protein involved in the regulation of tumor growth, invasion, dissemination and immunoreactivity in melanomas and other tumors, is expressed by almost all melanomas and melanoma metastases screened to date so far. Elevated levels of melanoma-inhibiting activity (MIA/CD-RAP) have also been measured in a subgroup of patients with advanced stage breast carcinomas.
MATERIALS AND METHODS: To further evaluate the extent and distribution of MIA/CD-RAP expression, early passage melanoma, glioma and other tumor cell lines as well as non-malignant cell lines were screened for the expression of MIA/CD-RAP by PCR, Western blot and immunohistochemistry.
RESULTS: All melanomas tested (n = 19) expressed high levels of MIA mRNA and protein. A high incidence of MIA expression was also found in glial tumors (6 out of 27). In contrast, MIA message (mRNA) could not be detected in non-glial CNS-tumors (n = 13). In addition, in CSF of patients harboring a brain tumor, significant higher levels of MIA protein were detectable compared to the systemic values. MIA/CD-RAP-message was detectable in 7 out of 20 systemic tumors, mainly carcinomas of the colon (2 out of 2) and, in low levels, in 8 out of 20 normal non-transformed cell cultures, for example fibroblasts and peripheral lymphocytes. These data indicate that MIA/CD-RAP is widely expressed in human and murine primary cell cultures and cell lines, with nevertheless relative high specificity for melanocytic tumors. Measurements of MIA protein in the cerebrospinal fluid (CSF) and serum of patients harboring metastatic melanoma revealed higher levels in the CSF than in serum. To address functional aspects of MIA/CD-RAP expression, we stably transformed a MIA/CD-RAP-negative glial tumor cell line to express MIA/CD-RAP. When tested in colony forming assay (CFA), these clones showed a marked reduction in colony formation.
CONCLUSION: According to these results, MIA/CD-RAP seems to exert a general function for invasive and metastatic tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12014625

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma.

Authors:  Alex Panaccione; Michael T Chang; Beatrice E Carbone; Yan Guo; Christopher A Moskaluk; Renu K Virk; Luis Chiriboga; Manju L Prasad; Benjamin Judson; Saral Mehra; Wendell G Yarbrough; Sergey V Ivanov
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

2.  MIA is a potential biomarker for tumour load in neurofibromatosis type 1.

Authors:  Mateusz Kolanczyk; Victor Mautner; Nadine Kossler; Rosa Nguyen; Jirko Kühnisch; Tomasz Zemojtel; Aleksander Jamsheer; Eike Wegener; Boris Thurisch; Sigrid Tinschert; Nikola Holtkamp; Su-Jin Park; Patricia Birch; David Kendler; Anja Harder; Stefan Mundlos; Lan Kluwe
Journal:  BMC Med       Date:  2011-07-04       Impact factor: 8.775

3.  Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.

Authors:  Su-Jin Park; Birgit Sawitzki; Lan Kluwe; Victor F Mautner; Nikola Holtkamp; Andreas Kurtz
Journal:  BMC Med       Date:  2013-04-23       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.